Optimer pays $20M to axe deal with Par
Optimer Pharma has regained the North American rights to Difimicin for Clostridium difficile-associated diarrhea from Par Pharmaceuticals. Optimer agreed to pay Par $20 million for the buy-back of Difimicin, which is in Phase IIb/III in North America. Optimer will also pay a $5 million milestone based on the successful commercialization of the therapy. Optimer was a 2006 Fierce 15 winner.
- see this press release from Par
- read the AP report for more
Related Article:
Optimer files IPO in bid to raise $86.3M. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
